The Future of Immuno-oncology in Advanced Lung Cancer

Videos — July 6, 2016

Featuring:

Benjamin P. Levy, MD, discusses the value in leveraging clinical trials to determine the potential of utilizing checkpoint inhibitors as single agent first line therapies and in combination with chemotherapy as a second line strategy.

Related Articles